Literature DB >> 9460743

Insulin-like growth factor-I modulation of cerebellar cell populations is developmentally stage-dependent and mediated by specific intracellular pathways.

I Torres-Aleman1, M Villalba, M P Nieto-Bona.   

Abstract

Although development of transgenic animals overexpressing insulin-like growth factor-I has allowed the establishment of a role of this trophic factor in brain growth, detailed knowledge of the action of insulin-like growth factor-I on different brain areas is still lacking. We now provide evidence for a pleiotrophic role of this growth factor on cerebellar development. Insulin-like growth factor-I produced by cerebellar cultures is a survival factor for Purkinje cells and a mitogen/differentiation factor for cerebellar glioblasts. Trophic effects of insulin-like growth factor-I were observed only during specific developmental stages. In addition, insulin-like growth factor-I increased intracellular Ca2+ levels in Purkinje cells and c-Fos in dividing glioblasts. Survival-promoting effects of insulin-like growth factor-I on Purkinje cells required activation of protein kinase C, while glioblast division induced by insulin-like growth factor-I depended on phosphatidylinosytol 3-kinase activation. We conclude that insulin-like growth factor-I is a paracrine/autocrine pleiotrophic factor for both glia and neurons in the cerebellum. Its effects are mediated by distinct intracellular signals and appear to be specific to the developmental stage of the target cell. Since development of the different cell populations that compose a specific brain territory is not synchronized, the pleiotrophic action of growth factors such as insulin-like growth factor-I may be essential to ontogenetic processes underlying normal brain growth.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9460743     DOI: 10.1016/s0306-4522(97)00367-9

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  12 in total

Review 1.  Revisiting the timing hypothesis: biomarkers that define the therapeutic window of estrogen for stroke.

Authors:  Farida Sohrabji; Amutha Selvamani; Robyn Balden
Journal:  Horm Behav       Date:  2012-06-19       Impact factor: 3.587

Review 2.  The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders.

Authors:  Jesse Costales; Alexander Kolevzon
Journal:  Neurosci Biobehav Rev       Date:  2016-01-15       Impact factor: 8.989

Review 3.  IGF-I in the clinics: Use in retinopathy of prematurity.

Authors:  Ann Hellström; David Ley; Ingrid Hansen-Pupp; Boubou Hallberg; Luca A Ramenghi; Chatarina Löfqvist; Lois E H Smith; Anna-Lena Hård
Journal:  Growth Horm IGF Res       Date:  2016-09-28       Impact factor: 2.372

Review 4.  Role of Insulinlike Growth Factor 1 in Fetal Development and in the Early Postnatal Life of Premature Infants.

Authors:  Ann Hellström; David Ley; Ingrid Hansen-Pupp; Boubou Hallberg; Luca A Ramenghi; Chatarina Löfqvist; Lois E H Smith; Anna-Lena Hård
Journal:  Am J Perinatol       Date:  2016-09-07       Impact factor: 1.862

Review 5.  Cell death in the nervous system: lessons from insulin and insulin-like growth factors.

Authors:  Isabel Varela-Nieto; Enrique J de la Rosa; Ana I Valenciano; Yolanda León
Journal:  Mol Neurobiol       Date:  2003-08       Impact factor: 5.590

6.  Insulin-like Growth Factor (IGF)-1 treatment stabilizes the microvascular cytoskeleton under ischemic conditions.

Authors:  Shameena Bake; Andre Okoreeh; Homa Khosravian; Farida Sohrabji
Journal:  Exp Neurol       Date:  2018-10-01       Impact factor: 5.330

7.  Fingerprint changes in CSF composition associated with different aetiologies in human neonatal hydrocephalus: inflammatory cytokines.

Authors:  Irum Naureen; Kh A Irfan Waheed; Ahsen W Rathore; Suresh Victor; Conor Mallucci; John R Goodden; Shahid N Chohan; Jaleel A Miyan
Journal:  Childs Nerv Syst       Date:  2014-04-15       Impact factor: 1.475

8.  Native and Complexed IGF-1: Biodistribution and Pharmacokinetics in Infantile Neuronal Ceroid Lipofuscinosis.

Authors:  Tuulia Huhtala; Jussi Rytkönen; Anu Jalanko; Martti Kaasalainen; Jarno Salonen; Raili Riikonen; Ale Närvänen
Journal:  J Drug Deliv       Date:  2012-06-15

9.  AF4 is a critical regulator of the IGF-1 signaling pathway during Purkinje cell development.

Authors:  Emmanuelle Bitoun; Mattéa J Finelli; Peter L Oliver; Sheena Lee; Kay E Davies
Journal:  J Neurosci       Date:  2009-12-09       Impact factor: 6.167

10.  Impaired SNF2L Chromatin Remodeling Prolongs Accessibility at Promoters Enriched for Fos/Jun Binding Sites and Delays Granule Neuron Differentiation.

Authors:  Laura R Goodwin; Gerardo Zapata; Sara Timpano; Jacob Marenger; David J Picketts
Journal:  Front Mol Neurosci       Date:  2021-07-06       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.